Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Plan B One-Step gets generic competition; legislation to restrict DXM introduced again; J&J agrees to reforms in settlement; China recants on MJN formula concerns; Buster line drives Hi-Tech Pharmacal OTC growth; Sabinsa awarded profits from infringed ForsLean trademark; more news In Brief.

You may also be interested in...



In Brief

Perrigo ships generic Mucinex extended-release; Valeant buys Obagi Medical Products; FDA advisory committee will discuss AERs; DXM legislation offered again; bill revived to allow Primatene Mist sales; Intercore will market MeliaLife products; more news In Brief.

Judge Dismisses Complaint Against McNeil Related To Recalled OTCs

A federal judge in Philadelphia tossed out a complaint alleging McNeil Consumer Healthcare overcharged for OTC products that the firm recalled due to quality control issues at its Fort Washington, Pa., facility beginning in 2010.

Judge Dismisses Complaint Against McNeil Related To Recalled OTCs

A federal judge in Philadelphia tossed out a complaint alleging McNeil Consumer Healthcare overcharged for OTC products that the firm recalled due to quality control issues at its Fort Washington, Pa., facility beginning in 2010.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel